abcl-8k_20220809.htm

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

__________________________________________________

FORM 8-K

__________________________________________________

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): August 9, 2022

__________________________________________________

ABCELLERA BIOLOGICS INC.

(Exact name of registrant as specified in its charter)

__________________________________________________

British Columbia		001-39781		Not Applicable
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification Number)

2215 Yukon Street

Vancouver, BC

V5Y 0A1

(Address of registrant’s principal executive office)

(Zip code)

(604) 559-9005

(Registrant’s telephone number, including area code)

(Former name or former address, if changed since last report)

__________________________________________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading symbol(s)	Name of each exchange on which registered
Common shares	ABCL	The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition

On August 9, 2022, AbCellera Biologics Inc., (the “Company”), issued a press release announcing its financial and operational results for the quarter ended June 30, 2022. A copy of the press release is furnished herewith as Exhibit 99.1.

Item 7.01 Regulation FD Disclosure

In connection with its earnings call on August 9, 2022, to discuss its results for the quarter ended June 30, 2022, the Company will utilize a corporate presentation, a copy of which is furnished herewith as Exhibit 99.2.

The information in Items 2.02 and 7.01 of this Form 8-K (including the exhibits attached hereto) is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, nor shall such information be deemed to be incorporated by reference in any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as otherwise stated in such filing.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits


Exhibit No.						Description
99.1						Press Release issued by AbCellera Biologics Inc. on August 9, 2022.
99.2						Corporate presentation.
104						Cover Page Interactive Data File (embedded as Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


Date: August 9, 2022	ABCELLERA BIOLOGICS INC.

	By:	/s/ Carl L. G. Hansen
		Carl L. G. Hansen, Ph.D.
		Chief Executive Officer and Director (Principal Executive Officer)

NEWS RELEASE

Exhibit 99.1

AbCellera Reports Q2 2022 Business Results

08/09/2022

●	Total revenue of $46 million, compared to $28 million in Q2 2021

●	Four program starts in the quarter bringing cumulative total to 88, up 47% from Q2 2021

●	Net loss of ($0.02) per share on a basic and diluted basis compared to ($0.01) (basic and diluted) per share in Q2 2021

VANCOUVER, British Columbia, August 9, 2022 -- AbCellera (Nasdaq: ABCL), a technology company with a centralized operating system for next-generation antibody discovery, today announced financial results for the second quarter of 2022. All financial information in this press release is reported in U.S. dollars, unless otherwise indicated.

“We have further strengthened our balance sheet as we execute on our strategy, extending our competitive advantage in antibody discovery and creating value through partnerships,” said Carl Hansen, Ph.D., CEO and President of AbCellera. “We continue to invest in technology development, including advancements in our CD3 bispecific platform for creating optimal T-cell-engager therapies for cancer, which we believe will create significant value for patients, our partners, and our shareholders.”

Q2 2022 Business Summary

●

Earned $46 million in total revenue.

●

Incurred net loss of $7 million, compared to a net loss of $2 million in Q2 2021.

●

Added six programs under contract with two new partners, resulting in a cumulative total of 164 programs under contract with 38 different partners.

●

Started discovery on four programs, bringing the cumulative number of program starts to 88.

●

Continuing to report six molecules cumulatively advanced to the clinic.

Key Business Metrics

Cumulative Metrics	June 30, 2021		June 30, 2022		Change %
Number of discovery partners		33		38		15	%
Programs under contract		138		164		19	%
Program starts		60		88		47	%
Molecules in the clinic		4		6		50	%

AbCellera added six discovery programs in Q2 to reach a cumulative total of 164 discovery programs as of June 30, 2022 (up from 138 on June 30, 2021), that are either completed, in progress, or under contract with 38 different partners (up from 33 on June 30, 2021). AbCellera started discovery on an additional four programs in Q2 to reach a cumulative total of 88 program starts (up from 60 on June 30, 2021). AbCellera’s partners have advanced a cumulative total of six molecules into the clinic.

Discussion of Q2 2022 Financial Results

●

Revenue – Total revenue was $45.9 million, compared to $27.6 million in Q2 2021. Royalties associated with bebtelovimab were $33.2 million. The partnership business produced research fees of $12.5 million, compared to $5.2 million in Q2 2021. Licensing revenue was $0.1 million.

●

Research & Development (R&D) Expenses – R&D expenses were $26.7 million, compared to $15.0 million in Q2 2021, reflecting continuing investments in the capacity and capabilities of AbCellera’s discovery and development platform.

●

Sales & Marketing (S&M) Expenses – S&M expenses were $3.1 million, compared to $1.3 million in Q2 2021.

●

General & Administrative (G&A) Expenses – G&A expenses were $14.4 million, compared to $11.2 million in Q2 2021, with the increase driven by investments to support the growth of the company.

●

Net Loss – Net loss was $6.8 million, or ($0.02) per share on both a basic and diluted basis compared to a net loss of $2.3 million, or ($0.01) per share on a basic and diluted basis in Q2 2021.

●

Liquidity – $1,022 million of cash, cash equivalents, and marketable securities.

Conference Call and Webcast

AbCellera will host a conference call and live webcast to discuss these results today at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time).

The live webcast of the earnings conference call can be accessed on the Events and Presentations section of AbCellera’s Investor Relations website. A replay of the webcast will be available through the same link following the conference call.

About AbCellera Biologics Inc.

AbCellera is a technology company that searches, decodes, and analyzes natural immune systems to find antibodies that its partners can develop into drugs to prevent and treat disease. AbCellera partners with drug developers of all sizes, from large

pharmaceutical to small biotechnology companies, empowering them to move quickly, reduce costs, and tackle the toughest problems in drug development. For more information, please visit www.abcellera.com.

Definition of Key Business Metrics

We regularly review the following key business metrics to evaluate our business, measure our performance, identify trends affecting our business, formulate financial projections, and make strategic decisions. We believe that the following metrics are important to understand our current business. These metrics may change or may be substituted for additional or different metrics as our business develops. For example, as our business matures and to the extent programs are discontinued, we anticipate updating these metrics to reflect such changes.

Number of discovery partners represents the unique number of partners with whom we have executed partnership contracts. We view this metric as an indication of the competitiveness of our technology stack and our current level of market penetration. The metric also relates to our opportunities to secure programs under contract.

Programs under contract represent the number of antibody development programs that are under contract for delivery of discovery research activities. A program under contract is counted when a contract is executed with a partner under which we commit to discover antibodies against one selected target. A target is any relevant antigen for which a partner seeks our support in developing binding antibodies. We view this metric as an indication of commercial success and technological competitiveness. It further relates to revenue from technology access fees. The cumulative number of programs under contract with downstream participation is related to our ability to generate future revenue from milestone payments and royalties.

Program starts represent the number of unique programs under contract for which we have commenced the discovery effort. The discovery effort commences on the later of (i) the day on which we receive sufficient reagents to start discovery of antibodies against a target and (ii) the day on which the kick-off meeting for the program is held. We view this metric as an indication of our operational capacity to execute on programs under contract. It is also an indication of the selection and initiation of discovery projects by our partners and the resulting near-term potential to earn research fees. Cumulatively, program starts with downstream participation indicate our total opportunities to earn downstream revenue from milestone fees and royalties in the mid- to long-term.

Molecules in the clinic represent the count of unique molecules for which an Investigational New Drug, or IND, New Animal Drug, or equivalent under other regulatory regimes, application has been approved based on an antibody that was discovered either by us or by a partner using licensed AbCellera technology. Where the date of such application approval is not known to us, the date of the first public announcement of a clinical trial will be used for the purpose of this metric. We view this metric as an indication of our near- and mid-term potential revenue from milestone fees and potential royalty payments in the long term.

AbCellera Forward-looking Statements

This press release contains forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements are based on management’s current beliefs and assumptions and on information currently available to management. All statements contained in this release other than statements of historical fact are forward-looking statements, including statements regarding our ability to develop, commercialize and achieve market acceptance of our current and planned products and services, our research and development efforts, and other matters regarding our business strategies, use of capital, results of operations and financial position, and plans and objectives for future operations.

In some cases, you can identify forward-looking statements by the words “may,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “ongoing” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. These risks, uncertainties and other factors are described under "Risk Factors," "Management's Discussion and Analysis of Financial Condition and Results of Operations" and elsewhere in the documents we file with the Securities and Exchange Commission from time to time. We caution you that forward-looking statements are based on a combination of facts and factors currently known by us and our projections of the future, about which we cannot be certain. As a result, the forward-looking statements may not prove to be accurate. The forward-looking statements in this press release represent our views as of the date hereof. We undertake no obligation to update any forward-looking statements for any reason, except as required by law.

Source: AbCellera Biologics Inc.

Inquiries

Media: Jessica Yingling, Ph.D.; [email protected], +1(236) 521-6774
Business Development: Murray McCutcheon; [email protected], +1(604) 559-9005
Investor Relations: Melanie Solomon; [email protected], +1(778) 729-9116

AbCellera Biologics Inc.
Condensed Consolidated Statements of Income (Loss) and
Comprehensive Income (Loss)
(All figures in U.S. dollars. Amounts are expressed in thousands except share and per share data)
(Unaudited)

	Three months ended June 30,						Six months ended June 30,
	2021			2022			2021			2022
Revenue:
Research fees	$	5,215		$	12,538		$	9,201		$	21,871
Licensing revenue		263			147			20,522			377
Milestone payments		1,000			-			8,000			-
Royalty revenue		21,165			33,232			192,661			340,249
Total revenue		27,643			45,917			230,384			362,497
Operating expenses:
Royalty fees		3,610			5,210			23,622			49,847
Research and development⁽¹⁾		15,046			26,685			27,403			53,052
Sales and marketing⁽¹⁾		1,295			3,120			3,869			5,490
General and administrative⁽¹⁾		11,203			14,412			17,688			28,680
Depreciation and amortization		3,522			4,886			6,827			8,875
Total operating expenses		34,676			54,313			79,409			145,944
Income (loss) from operations		(7,033	)		(8,396	)		150,975			216,553
Other (income) expense
Other (income) expense		(314	)		25			(645	)		(641	)
Grants and incentives		(4,646	)		(1,535	)		(7,794	)		(6,730	)
Total other (income)		(4,960	)		(1,510	)		(8,439	)		(7,371	)
Net earnings (loss) before income tax		(2,073	)		(6,886	)		159,414			223,924
Income tax (recovery) expense		250			(101	)		44,516			62,136
Net earnings (loss)	$	(2,323	)	$	(6,785	)	$	114,898		$	161,788
Foreign currency translation adjustment		2,152			(211	)		2,152			296
Comprehensive income (loss)	$	(171	)	$	(6,996	)	$	117,050		$	162,084

Net earnings (loss) per share attributable to common shareholders
Basic	$	(0.01	)	$	(0.02	)	$	0.42		$	0.57
Diluted	$	(0.01	)	$	(0.02	)	$	0.36		$	0.52
Weighted-average common shares outstanding
Basic		272,196,107			284,686,542			270,953,541			284,292,312
Diluted		272,196,107			284,686,542			321,555,443			313,361,183

(1)

Exclusive of depreciation and amortization

AbCellera Biologics Inc.
Condensed Consolidated Balance Sheet
(All figures in U.S. dollars. Amounts are expressed in thousands except share data)
(Unaudited)

	December 31, 2021		June 30, 2022
Assets
Current assets:
Cash and cash equivalents	$	476,142	$	790,615
Marketable securities		246,835		231,652
Total cash, cash equivalents, and marketable securities		722,977		1,022,267
Accounts and accrued receivable		160,576		52,797
Restricted cash		25,000		25,000
Other current assets		21,247		43,891
Total current assets		929,800		1,143,955
Long-term assets:
Property and equipment, net		111,616		149,178
Intangible assets, net		148,392		143,179
Goodwill		47,806		47,806
Investments in and loans to equity accounted investees		50,313		65,824
Other long-term assets		30,642		43,842
Total long-term assets		388,769		449,829
Total assets	$	1,318,569	$	1,593,784
Liabilities and shareholders' equity
Current liabilities:
Accounts payable and other liabilities	$	32,017	$	24,390
Current portion of contingent consideration payable		22,934		34,252
Income taxes payable		35,683		107,322
Accrued royalties payable		22,506		50,555
Deferred revenue		7,536		4,621
Total current liabilities		120,676		221,140
Long-term liabilities:
Operating lease liability		36,413		32,759
Deferred revenue and grant funding		60,758		64,800
Contingent consideration payable		35,886		24,629
Deferred tax liability		37,370		34,616
Other long-term liabilities		1,733		2,984
Total long-term liabilities		172,160		159,788
Total liabilities		292,836		380,928
Commitments and contingencies
Shareholders' equity:
Common shares: no par value, unlimited authorized shares at December 31, 2021 and June 30, 2022: 283,257,104 and 285,052,302 shares issued and outstanding at December 31, 2021 and June 30, 2022, respectively		722,430		726,825
Additional paid-in capital		35,357		56,001
Accumulated other comprehensive income		280		576
Accumulated earnings		267,666		429,454
Total shareholders' equity		1,025,733		1,212,856
Total liabilities and shareholders' equity	$	1,318,569	$	1,593,784

AbCellera Biologics Inc.
Condensed Consolidated Statement of Cash Flows
(Expressed in thousands of U.S. dollars)
(Unaudited)

	Six months ended June 30,
	2021			2022
Cash flows from operating activities:
Net income	$	114,898		$	161,788
Cash flows from operating activities:
Depreciation of property and equipment		1,897			3,681
Amortization of intangible assets		4,930			5,213
Amortization of operating lease right-of-use assets		1,354			2,120
Stock-based compensation		13,900			24,404
Other		337			(298	)
Changes in operating assets and liabilities:
Accounts and accrued research fees receivable		(28,339	)		(6,963	)
Accrued royalties receivable		172,768			106,583
Income taxes payable		(30,330	)		52,251
Accounts payable and accrued liabilities		(3,640	)		(1,882	)
Deferred revenue		4,848			(2,979	)
Accrued royalties payable		(3,623	)		28,049
Deferred grant revenue		22,349			5,406
Other assets		(4,121	)		(4,139	)
Net cash provided by operating activities		267,228			373,234
Cash flows from investing activities:
Purchases of property and equipment		(40,448	)		(45,817	)
Purchase of marketable securities		-			(134,306	)
Proceeds from marketable securities		-			145,808
Receipt of grant funding		4,520			8,098
Long-term investments and other assets		(5,034	)		(11,657	)
Investment in and loans to equity accounted investees		(20,510	)		(15,694	)
Net cash used in investing activities		(61,472	)		(53,568	)
Cash flows from financing activities:
Repayment of long-term debt and contingent consideration		(4,373	)		(73	)
Proceeds from debt and exercise of stock options		2,755			2,175
Payment of liability for in-licensing agreement		(5,000	)		(4,060	)
Net cash used in financing activities		(6,618	)		(1,958	)
Effect of exchange rate changes on cash and cash equivalents		(683	)		(1,411	)
Increase in cash and cash equivalents		198,455			316,297
Cash and cash equivalents and restricted cash, beginning of period		594,116			501,142
Cash and cash equivalents and restricted cash, end of period	$	792,571		$	817,439
Restricted cash included in other assets		-			(1,824	)
Total cash, cash equivalents, and restricted cash shown in the statement of cash flows	$	792,571		$	815,615
Supplemental disclosure of non-cash investing and financing activities
Property, plant and equipment in accounts payable		-			2,146
Right-of-use assets obtained in exchange for operating-lease obligation		29,573			(796	)

Exhibit 99.2 AbCellera Q2 2022 BUSINESS UPDATE AUGUST 9, 2022 COPYRIGHT ABCELLERA

DISCLAIMER Q2 2022 BUSINESS UPDATE This presentation contains forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements are based on management's beliefs and assumptions and on information currently available to management. All statements contained in this presentation other than statements of historical fact are forward-looking statements, including statements regarding our ability to develop, commercialize and achieve market acceptance of our current and planned products and services, our research and development efforts, and other matters regarding our business strategies, use of capital, results of operations and financial position, and plans and objectives for future operations. In some cases, you can identify forward-looking statements by the words "may," "will," "could," "would," "should," "expect," "intend," "plan," "anticipate," "believe," "estimate," "predict," "project," "potential," "continue," "ongoing or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. These risks, uncertainties and other factors are described under "Risk Factors," "Management's Discussion and Analysis of Financial Condition and Results of Operations" and elsewhere in the documents we file with the Securities and Exchange Commission from time to time. We caution you that forward-looking statements are based on a combination of facts and factors currently known by us and our projections of the future, about which we cannot be certain. As a result, the forward-looking statements may not prove to be accurate. The forward-looking statements in this presentation represent our views as of the date hereof. We undertake no obligation to update any forward-looking statements for any reason, except as required by law.COPYRIGHT © ABCELLERA 2

Q2 2022. BUSINESS UPDATE SUMMARY. MAINTAINING A STRONG CASH POSITION & EXPANDING COMPETITIVE ADVANTAGE Current environment presents challenges for would-be competitors, extending our competitive advantage significantly. Our business model provides value to companies prioritizing innovation, efficiency and capital preservation. Rationalization across the industry will likely lead to a consolidation of talent. $1B+ in cash, cash equivalents & marketable securities 164 cumulative programs under contract 88 cumulative programs started

COPYRIGHT © ABCELLERA Q2 2022. BUSINESS UPDATE TECHNOLOGY AS A LEVER TARGET TO IND IS ONE OF THE MOST COMPLEX & TECHNOLOGY – INTENSIVE PATHS IN ANY SECTOR Target Identification IDEATION Drug Discovery regulations, technology, science, manufacturing, lab space, talent 1000+ steps PRODUCT CREATION 3 to 5 years Clinical Development PRODUCT TESTING 7 to 10 years 4

VALUE CREATION SIGNIFICANT OPPORTUNITIES TO UNLOCK VALUE We aim to deliver value in three ways: by making drug development faster by doing things that haven't been done before by leveling the playing field for partners, to empower a broad ecosystem of innovators Q2 2022 BUSINESS UPDATE $200M+ NPV by accelerating approval of an average antibody drug by 1 year Billions sales, profit, value by being first to market $100B+ unlocked by drugging the undruggable new market opportunities Millions small biotech savings from not having to reinvent the wheel 5 copyright © abcellera

Partnership PARTNERING WITH PREMIER VENTURE CAPITAL FIRMS TO UNLOCK EARLY-STAGE INNOVATORS 6 PORTFOLIO COMPANY OF NEW PROGRAMS UNDER CONTRACT ATLAS VENTURE 8 POTENTIAL PROGRAMS undisclosed PORTFOLIO COMPANIES OF VERSANT ventures Q2 2022 BUSINESS UPDATE 3 targets multi-year targets multi-year multiple indications 3 multiple indications copyright © abcellera 6

TECHNOLOGY DEVELOPMENT T-CELL ENGAGER PLATFORM Q2 2022 BUSINESS UPDATE COPYRIGHT © ABCELLERA 7 ADVANCING NEW T-CELL ENGAGER CANCER THERAPIES Our data indicate that our CD3 panel of 200+ unique antibodies bind to a wide variety sites on the CD3 complex and is capable of constructing bispecifics antibodies with a very wide range of functional activities, exactly what is needed to build tunable, optimized therapeutic T-cell engagers. CD3 + EGFR BISPECIFIC ANTIBODIES PROOF OF CONCEPT Bispecifics induced a wide range of T cell activation. Bispecifics were identified that effectively kill tumor cells with either no or very low cytokine release, suggesting these molecules could overcome key hurdles to getting into the clinic.

TECHNOLOGY DEVELOPMENT PRE-PARTNERED PROGRAMS TECH DEVELOPMENT MAY GENERATE ASSETS FOR PARTNERING Pandemic Response Platform 02 2022 BUSINESS UPDATE COPYRIGHT © ABCELLERA 8 PANDEMIC Response Platform Technology-intensive challenge requiring complex Integration to deliver antibody therapies quickly and bring new treatments to address emerging variants. T-Cell Engager Platform Untapped market opportunity in an area with a high technical barrier to entry and a rich target space that includes many targets. GPCRs & lon Channels Platform High-value, well-validated targets that have been intractable using fragmented approaches and traditional technology.

TECHNOLOGY DEVELOPMENT, VALUE OF PRE-PATNERED PROGRAMS Q2 2022 BUSINESS UPDATE 2 YEARS OF TECH DEVELOPMENT 2 COVID ANTIBODY TREATMENTS 2.5M + PATIENTS TREATED We had Spent 2 years developing our technology specially for pandemic response prior to the emergence of COVID-19 and initiated our work before entering into a partnership with Eli Lilly. Bamlanivimab was the first antibody to be authorized by FDA, and bebtelovimab continues to be used to combat the virus, remains effective against all known variants of concern, and is still the most potent COVID-19 antibody treatment available. COPYRIGHT © ABCELLERA 9

Strong portfolio growth cumulative # of program starts cumulative # of molecules in the clinic total # of programs under contracts 164 total # of discovery partners 38 q2 2022 business update financials (bar graph) -without downstream participation + with downstream participation (bar graph) note: showing year-end figures expect for most recent quarter.historical results are not necessarily indicative of future results COPYRIGHT © ABCELLERA 11

Q2 2022 business update financials 6 molecules in the clinic molecules bamlanivimab (ly-cov555) bebtelovimab (ly-cov1404) nbl-012 nbl-015 undisclosed IVX-01 stage marketed, emergency use authorization (EUA) phase 1 completed IND/CTA authorized IND/CTA authorized IND/CTA authorized clinical field study partner lilly lilly novarock botherapeutics novarock botherapeutics undisclosed invetx therapeutic area infectious disease-covid-19 infectious disease-covid-19 dermatology gastrointestinal disease immunology oncology undisclosed animal healthprogram type abcellera discovery partnership trianni license abcellera discovery partnership COPYRIGHT © ABCELLERA 12

$45.9M Total revenue, driven by royalties for bebtelovimab. Revenue USD ROYALTIES MILESTONES LICENSING RESEARCH FEES $27.6M $21.2M $0.3M $1.0M $5.2M Q2 2021 $45.9M $33.2M $12.5M $0.1M Q2 2022 COPYRIGHT © ABCELLERA Q2 2022 BUSINESS UPDATE FINANCIALS 13

Operating expenses reflect strengthening of the platform. Operating Expenses USD RESEARCH & DEVELOPMENT +$11.6M $15.0M $26.7M Q2 2021 Q2 2022 SALES & MARKETING +$1.8M $1.3M Q2 2021 $3.1M Q2 2022 GENERAL & ADMIN +$3.2M $11.2M Q2 2021 $14.4M Q2 2022 COPYRIGHT © ABCELLERA Q2 2022 BUSINESS UPDATE FINANCIALS 14

Net loss of $6.8M: equivalent to $0.02 (basic and diluted) Per share. Earning USD NET EARNINGS -$2.3M Q2 2021 -$6.8M Q2 2022 EARNINGS PER SHARE: BASIC AND DILUTED -$0.01 Q2 2021 -$0.02 Q2 2022 COPYRIGHT © ABCELLERA Q2 2022 BUSINESS UPDATE FINANCIALS 15

Over $1 billion in total cash, equivalents, and marketable securities. Cash Flows USD $748M $247M $476M $25M 31-Dec-21 $373M OPERATING ($54M) INVESTING ($2M) FINANCING ($1M) FX $1,049M $232M Marketable Securities $792M Cash & Equivalents $25M Restricted Cash 30-June-22 COPYRIGHT © ABCELLERA Q2 2022 BUSINESS UPDATE FINANCIALS 16